Diabetic neuropathy is one of the most common and serious complications of diabetes mellitus and metabolic syndrome. The current therapy strategies, including glucose control and pain management, are not effective for most patients. Growing evidence suggests that infiltration of inflammation factors and deficiency of local neurotrophic and angiogenic factors contribute significantly to the pathologies of diabetic neuropathy. Experimental and clinical studies have shown that bone marrow-derived stem cells (BMCs) therapy represents a novel and promising strategy for tissue repair through paracrine secretion of multiple cytokines, which has a potential to inhibit inflammation and promote angiogenesis and neurotrophy in diabetic neuropathy. In this review, we discuss the clinical practice in diabetic neuropathy and the therapeutic effect of BMC. We subsequently illustrate the functional impairment of autologous BMCs due to the interrupted bone marrow niche in diabetic neuropathy. We anticipate that the functional restoration of BMCs could improve their therapeutic effect and enable their wide applications in diabetic neuropathy.
[1]Beijing Haidian Hosp, Dept Neurol, Beijing 100080, Peoples R China.
[2]Harvard Med Sch, Brigham & Womens Hosp, Div Engn Med, Cambridge, MA 02139 USA.
[3]MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
[4]Peking Univ, Dept Neurol, Hosp 3, Beijing 100191, Peoples R China.
[5]Fudan Univ, Zhongshan Hosp, Dept Cardiac Surg, Shanghai 200032, Peoples R China.
[6]Shanghai Inst Cardiovasc Dis, Shanghai 200032, Peoples R China.
(8.0+极速模式)